Equity · Healthcare
CTNM
NASDAQContineum Therapeutics (CTNM)
The line runs 13.82 USD on 15 September through 9 USD on 12 October, on a scale from 8 to 14. Days the market did not trade hold the previous close, flat.
- Market cap
- 207.9M USD
- EPS, diluted, year to Dec 2025
- −2.17 USD
- 52-week range
- 9 USD – 16 USD
- Avg volume
- 70.9K
as of Oct 12, 2026
Have Contineum Therapeutics (CTNM) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Contineum Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 23 Dec 2025, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 8 Sep 2026
Buys 0Sells 1Net sold $41KOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Sep 2026 | Stengone Carmine N.CEO and President | Sell | 2,500 | 41K USD |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Sep 2026 | Stengone Carmine N.CEO and President | Option exercise | 2,500 | 3K USD |
Which funds hold Contineum Therapeutics (CTNM)?
7 of the 45 institutional funds we track reported a Contineum Therapeutics position for the quarter ended 30 Jun 2026 — a combined 50.7M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Balyasny Asset Management | Held (±25%) | 1,522,793 | 25.0M USD | −9.7% |
| Millennium Management | Trimmed | 931,709 | 15.3M USD | −39.3% |
| Citadel Advisors | Held (±25%) | 396,354 | 6.5M USD | +13.2% |
| Marshall Wace | Trimmed | 118,058 | 1.9M USD | −47.8% |
| Renaissance Technologies | Held (±25%) | 67,300 | 1.1M USD | −3.0% |
| Two Sigma Investments | Held (±25%) | 30,347 | 497K USD | −20.0% |
| Point72 Asset Management | Trimmed | 25,779 | 423K USD | −69.6% |
| Baker Bros. Advisors | Exited |
What has been filed or recorded for Contineum Therapeutics (CTNM)?
The filings we hold for Contineum Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 205 shares | 3K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.49 USD | |
| 30 Sep 2026 | Financials | Total assets | 257.0M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 245.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.40 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.39 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.17 USD | |
| 31 Dec 2025 | Financials | Net income | −60.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.17 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2026 reported | EPS −0.45 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2026 reported | EPS −0.62 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2026 reported | EPS −0.62 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.18 USD |
Contineum Therapeutics (CTNM): frequently asked questions
What did Contineum Therapeutics shares close at?
Contineum Therapeutics closed at 9.00 USD on 12 Oct 2026, down 32.79% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Contineum Therapeutics’ market cap?
Contineum Therapeutics is worth 207.9M USD by market value as of 12 Oct 2026, which is the share price times the shares on issue from its SEC filings.
Have Contineum Therapeutics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Contineum Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 23 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Contineum Therapeutics?
7 of the 45 funds we track reported a Contineum Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Balyasny Asset Management, Millennium Management and Citadel Advisors. See Funds
When did Contineum Therapeutics last report earnings?
Contineum Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.49 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings